Meeting Notice No. 7-06, 48948 [06-7103]
Download as PDF
<![CDATA[
48948
Federal Register / Vol. 71, No. 162 / Tuesday, August 22, 2006 / Notices
The Institute will manufacture small
quantities of cocaine and marihuana
derivatives for use by their customers in
analytical kits, reagents, and reference
standards as directed by NIDA.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than October 23, 2006.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13841 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
cprice-sewell on PROD1PC66 with NOTICES
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on May 12,
2006, Wildlife Laboratories, Inc., 1401
Duff Drive, Suite 400, Fort Collins,
Colorado 80524, made application to the
Drug Enforcement Administration
(DEA) by renewal to be registered as an
importer of Etorphine Hydrochloride
(9059), a basic class of controlled
substance listed in Schedule II.
The company plans to import the
listed controlled substance for sale to its
customers.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
VerDate Aug<31>2005
15:34 Aug 21, 2006
Jkt 208001
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 21, 2006.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
Schedule I or II are, and will continue
to be required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13842 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated April 17, 2006, and
published in the Federal Register on
April 21, 2006, (71 FR 20729), Guilford
Pharmaceuticals, Inc., 6611 Tributary
Street, Baltimore, MD 21224, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Cocaine (9041), a basic class of
controlled substance listed in Schedule
II.
The company plans to manufacture a
cocaine derivative to be used in clinical
research studies.
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Guilford Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Guilford Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: August 15, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–13848 Filed 8–21–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Foreign Claims Settlement
Commission
Meeting Notice No. 7–06
The Foreign Claims Settlement
Commission, pursuant to its regulations
(45 CFR part 504) and the Government
in the Sunshine Act (5 U.S.C. 552b),
hereby gives notice in regard to the
scheduling of meetings for the
transaction of Commission business and
other matters specified, as follows:
DATE AND TIME: Thursday, August 31,
2006, at 10 a.m.
SUBJECT MATTER: Issuance of Proposed
Decisions and Amended Final Decisions
in claims against Albania.
STATUS: Open.
All meetings are held at the Foreign
claims Settlement Commission, 600 E
Street, NW., Washington, DC. Requests
for information, or advance notices of
intention to observe an open meeting,
may be directed to: Administrative
Officer, Foreign Claims Settlement
Commission, 600 E Street, NW., Room
6002, Washington, DC 20579.
Telephone: (202) 616–6988.
Dated at Washington, DC.
Mauricio J. Tamargo,
Chairman.
[FR Doc. 06–7103 Filed 8–18–06; 1:36 pm]
BILLING CODE 4410–01–P
E:\FR\FM\22AUN1.SGM
22AUN1
]]>Agencies
[Federal Register Volume 71, Number 162 (Tuesday, August 22, 2006)]
[Notices]
[Page 48948]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-7103]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Foreign Claims Settlement Commission
Meeting Notice No. 7-06
The Foreign Claims Settlement Commission, pursuant to its
regulations (45 CFR part 504) and the Government in the Sunshine Act (5
U.S.C. 552b), hereby gives notice in regard to the scheduling of
meetings for the transaction of Commission business and other matters
specified, as follows:
Date and Time: Thursday, August 31, 2006, at 10 a.m.
Subject Matter: Issuance of Proposed Decisions and Amended Final
Decisions in claims against Albania.
Status: Open.
All meetings are held at the Foreign claims Settlement Commission,
600 E Street, NW., Washington, DC. Requests for information, or advance
notices of intention to observe an open meeting, may be directed to:
Administrative Officer, Foreign Claims Settlement Commission, 600 E
Street, NW., Room 6002, Washington, DC 20579. Telephone: (202) 616-
6988.
Dated at Washington, DC.
Mauricio J. Tamargo,
Chairman.
[FR Doc. 06-7103 Filed 8-18-06; 1:36 pm]
BILLING CODE 4410-01-P
